Please use this identifier to cite or link to this item:
|Title:||Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: A pilot study on a series of 56 patients|
|Authors:||Matarraz, Sergio; López, Antonio; Barrena, Susana; Fernández, Carlos; Jensen, Evan; Flores, Juan; Rasillo, Ana; Sayagués, José María; Sánchez, Maria Luz; Bárcena, Paloma; Hernández, Jesús M.; Orfao, Alberto|
|Citation:||Cytometry PartB: Clinical Cytometry 78(3): 154-168 (2010)|
|Abstract:||A heterogeneous spectrum of immunophenotypic abnormalities have been reported in myelodysplastic syndromes (MDS). However, most studies are restricted to the analysis of CD34+ cells and/or other major subsets of CD34- cells, frequently not exploring the diagnostic and prognostic impact of immunophenotyping. Methods: We propose for the first time an immunophenotypic score (IS) based on the altered distribution and immunophenotypic features of maturing/mature compartments of bone marrow (BM) hematopoietic cells in 56 patients with MDS that could contribute to a refined diagnosis and prognostic evaluation of the disease. Results: Although MDS-associated phenotypes were detected in reactive BM, the overall immunophenotypic profile of BM cells allowed an efficient discrimination between MDS and both normal and reactive BM, once the number and degree of severity of the abnormalities detected per patient were simultaneously considered in the proposed IS. Interestingly, increasingly higher IS were found among patients with MDS showing adverse prognostic factors and in low- versus high-grade cases. The most informative prognostic factors included the number of CD34+ cells, presence of aberrant CD34-/CD117+ precursors, decreased mature neutrophils and CD34- erythroid precursors, and increased numbers of CD361/lo erythroid precursors; in addition, the IS was an independent prognostic factor for overall survival. Conclusions: Assessment of immunophenotypic abnormalities of maturing/mature BM cells allows an efficient discrimination between MDS and both normal and reactive BM, once the number and degree of severity of the abnormalities detected are simultaneously scored. Interestingly, progressively higher IS were found among patients with MDS with adverse prognostic features and shorter overall survival. © 2010 Clinical Cytometry Society.|
|Appears in Collections:||(IBMCC) Artículos|
Show full item recordCSIC SFX Links
WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.